Excelsyn strikes celestial deal

Published: 1-Apr-2006

UK group Excelsyn has acquired a minority 18% stake in Angel Biotechnology, a contract bio-process development and manufacturing company, as the two companies aim to establish a deeper strategic partnership.


UK group Excelsyn has acquired a minority 18% stake in Angel Biotechnology, a contract bio-process development and manufacturing company, as the two companies aim to establish a deeper strategic partnership.

The move follows Angel's successful listing on the UK AIM (Alternative Investment Market) in mid-November 2005.

"Taking a position in Angel fitted our agenda to leverage our biotransformation technology and further increase involvement in the biotech sector," said group chairman Ian Shott. "Our investment in a strategic partnership complements our existing portfolio of services and IP, and continues the "cluster"-driven business model."

Excelsyn has been working with Angel through its engineering technology service cluster to build a state-of-the-art fermentation facility at Angel's site in Cramlington, UK. This led to an introduction to the company's molecular development cluster, which is developing Excelsyn's IP portfolio, including biotechnology and biotransformations, and application to the production of unnatural, chiral amino acids.

Meanwhile Excelsyn Molecular Development has been awarded two DTI-funded Knowledge Transfer Partnership (KTP) grants to further develop its catalyst technology and enhance its capability in analytical methodology.

You may also like